Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer	Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2021	View \| Download
Capivasertib with paclitaxel for previously untreated locally advanced or metastatic triple-negative breast cancer	Capivasertib , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2023	View \| Download
Atezolizumab with paclitaxel and carboplatin for previously untreated advanced endometrial cancer	Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2019	View \| Download
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406)	Ovarian cancer	Female Reproductive Cancer	2018	View \| Download